Canadian Liver Foundation

Trana Discovery, a drug discovery technology company, aims to help its partners find classes of drugs for the treatment of serious viral, fungal, and bacterial infectious diseases. The technology identifies compounds that work through a mechanism of action: inhibition of the target pathogen's ability to use transfer RNA (tRNA) essential for protein synthesis or replication. The use of Trana Discovery technology can unlock the value " scientific, human, and financial " hidden in drug compound libraries, expedite the discovery of drugs, and provide opportunities for exclusive rights to drug classes.

The completion of the human genome sequence has created new and opportunities for the biotechnology industry to develop therapeutics. nnProtEra is a brilliant biotech company focused on the creation, development and distribution of target bio-molecules and new methods for the drug discovery. ProtEra was founded in 2003 by three scientists of the Magnetic Resonance Center (CERM) of the University of Florence. nProtEra's headquarter is based in the Scientific Campus of the University of Florence in Sesto Fiorentino. CERM, with its basket of technologies in post-genomic structural and computational biology, is "incubating" ProtEra during its initial phase. Before completing its full expansion, ProtEra accesses, through agreements with CERM, to high magnetic field NMR spectrometers equipped with high sensitivity probes (cryo-probes).

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

Service On-Site offers maintenance, repair and refurbishment for major medical equipment. Their customers include hospitals, surgery centers, and doctors' offices.

Bio-Signal Group (BSG) was established in July 2002. Shortly after that, BSG started supplying devices which support behavioral experiments in laboratories throughout Europe. Its goal is to work with affiliated scientists and laboratories for identifying interesting and far-reaching neuroscience technology, and playing a lead role in its development and commercialization. For fulfillment of this goal, BSG aims to bring the best available human resources, private finance and develop strategic partnerships with neuroscientists and private businesses. BSG's partners and affiliates are a group of scientists and researchers who have been related to each other over a long period of intensive scientific work, research and academic debates over their innovative ideas and scientific projects. BSG is a commercial entity. Its business model is built around commercialization of the technology. In pursuit of its business objectives, BSG is committed to protecting and respecting proprietary rights and interests of the affiliated scientists by providing them adequate moral and financial compensation for their achievements, efforts and innovative ideas. Bio-Signal Group offices are located at the SUNY Technology Center in Brooklyn , NY .

Heartland Information Services specializes in high-quality, full-service medical transcription providing financial and service advantages that helps its clients reach or exceed goals. Heartland provides unparalleled efficiency, reliability and management capabilities while interfacing with virtually any health information system and software. Heartland's corporate headquarters is located in Toledo, Ohio, with work centers in Bangalore, Chennai, and Delhi, India.